Skip to main content

Advertisement

Log in

Identification of Differentially Expressed K-Ras Transcript Variants in Patients With Leiomyoma

  • Original Article
  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

Purpose

Molecular studies have demonstrated a wide range of gene expression variations in uterine leiomyoma. The rat sarcoma virus/rapidly accelerated fibrosarcoma/mitogen-activated protein kinase (RAS/RAF/MAPK) is the crucial cellular pathway in transmitting external signals into nucleus. Deregulation of this pathway contributes to excessive cell proliferation and tumorigenesis. The present study aims to investigate the expression profile of the K-Ras transcripts in tissue samples from patients with leiomyoma.

Methods

The patients were leiomyoma cases who had no mutation in mediator complex subunit 12 (MED12) gene. A quantitative approach has been applied to determine the difference in the expression of the 2 main K-Ras messenger RNA (mRNA) variants. The comparison between gene expression levels in leiomyoma and normal myometrium group was performed using relative expression software tool.

Results

The expression of K-Ras4B gene was upregulated in leiomyoma group (P =.016), suggesting the involvement of K-Ras4B in the disease pathogenesis. Pairwise comparison of the K-Ras4B expression between each leiomyoma tissue and its matched adjacent normal myometrium revealed gene upregulation in 68% of the cases. The expression of K-Ras4A mRNA was relatively upregulated in leiomyoma group (P =.030). In addition, the mean expression of K-Ras4A gene in leiomyoma tissues relative to normal samples was 4.475 (95% confidence interval: 0.10-20.42; standard error: 0.53-12.67). In total, 58% of the cases showed more than 2-fold increase in K-Ras4A gene expression.

Conclusion

Our results demonstrated increased expression of both K-Ras mRNA splicing variants in leiomyoma tissue. However, the ultimate result of KRAS expression on leiomyoma development depends on the overall KRAS isoform balance and, consequently, on activated signaling pathways.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Lippman SA, Warner M, Samuels S, Olive D, Vercellini P, Eskenazi B. Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril. 2003;80(6):1488–1494.

    Article  PubMed  Google Scholar 

  2. Ono M, Qiang W, Serna VA, et al. Role of stem cells in human uterine leiomyoma growth. PloS One. 2012;7(5):e36935. doi:10.1371/journal.pone.0036935.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wise LA, Palmer JR, Harlow BL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol. 2004;159(2):113–123.

    Article  PubMed  Google Scholar 

  4. Maruo T, Ohara N, Yoshida S, et al. Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system. Contraception. 2010;82(5):435–441. doi:10.1016/j.contraception.2010.05.006.

    Article  CAS  PubMed  Google Scholar 

  5. Morkel M, Riemer P, Blaker H, Sers C. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget. 2015;6(25):20785–20800. doi:10.18632/oncotarget.4750.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Molina JR, Adjei AA. The Ras/Raf/MAPK pathway. J Thorac Oncol. 2006;1(1):7–9.

    Article  PubMed  Google Scholar 

  7. Shahrabi-Farahani M, Shahbazi S, Mahdian R, Amini-Moghaddam S. K-Ras 4A transcript variant is up-regulated in eutopic endometrium of endometriosis patients during proliferative phase of menstrual cycle. Arch Gynecol Obstetr. 2015;292(1):225–229. doi:10.1007/s00404-014-3596-7.

    Article  Google Scholar 

  8. Voice JK, Klemke RL, Le A, Jackson JH. Four human Ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem. 1999;274(24):17164–17170.

    Article  CAS  PubMed  Google Scholar 

  9. Plowman SJ, Williamson DJ, O’Sullivan MJ, et al. While K-Ras is essential for mouse development, expression of the K-Ras 4A splice variant is dispensable. Mol Cell Biol. 2003;23(24):9245–9250.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Shahbazi S, Fatahi N, Amini-Moghaddam S. Somatic mutational analysis of MED12 exon 2 in uterine leiomyomas of Iranian women. Am J Cancer Res. 2015;5(8):2441–2446.

    PubMed  PubMed Central  Google Scholar 

  11. Almeida TA, Quispe-Ricalde A, Montes de Oca F, Foronda P, Hernandez MM. A high-throughput open-array qPCR gene panel to identify housekeeping genes suitable for myometrium and leiomyoma expression analysis. Gynecol Oncol. 2014;134(1):138–143. doi:10.1016/j.ygyno.2014.04.012.

    Article  CAS  PubMed  Google Scholar 

  12. Ciarmela P, Islam MS, Reis FM, et al. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update. 2011;17(6):772–790. doi:10.1093/humupd/dmr031.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Yeh J, Rein M, Nowak R. Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometria and leiomyomata. Fertil Steril. 1991;56(5):997–1000.

    Article  CAS  PubMed  Google Scholar 

  14. Harrison-Woolrych ML, Charnock-Jones DS, Smith SK. Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J Clin Endocrinol Metab. 1994;78(5):1179–1184. doi:10.1210/jcem.78.5.8175976.

    CAS  PubMed  Google Scholar 

  15. Fotiou SK, Tserkezoglou AJ, Mahera H, et al. Chromosome aberrations and expression of Ras and myc oncogenes in leiomyomas and a leiomyosarcoma of the uterus. Eur J Gynaecol Oncol. 1992;13(4):340–345.

    CAS  PubMed  Google Scholar 

  16. Hall KL, Teneriello MG, Taylor RR, et al. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas. Gynecol Oncol. 1997;65(2):330–335. doi:10.1006/gyno.1997.4653.

    Article  CAS  PubMed  Google Scholar 

  17. Jancik S, Drabek J, Radzioch D, Hajduch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol. 2010;2010:150960. doi:10.1155/2010/150960.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Plowman SJ, Berry RL, Bader SA, et al. K-Ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer. J Exp Clin Cancer Res. 2006;25(2):259–267.

    CAS  PubMed  Google Scholar 

  19. Nussinov R, Tsai CJ, Chakrabarti M, Jang H. A new view of Ras isoforms in cancers. Cancer Res. 2016;76(1):18–23. doi:10.1158/0008-5472.CAN-15-1536.

    Article  CAS  PubMed  Google Scholar 

  20. Tsai FD, Lopes MS, Zhou M, et al. K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif. Proc Natl Acad Sci U S A. 2015;112(3):779–784. doi:10.1073/pnas.1412811112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Brooks DG, James RM, Patek CE, Williamson J, Arends MJ. Mutant K-Ras enhances apoptosis in embryonic stem cells in combination with DNA damage and is associated with increased levels of p19(ARF). Oncogene. 2001;20(17):2144–2152. doi:10.1038/sj.onc.1204309.

    Article  CAS  PubMed  Google Scholar 

  22. James RM, Arends MJ, Plowman SJ, et al. K-Ras proto-oncogene exhibits tumor suppressor activity as its absence promotes tumorigenesis in murine teratomas. Mol Cancer Res. 2003;1(11):820–825.

    CAS  PubMed  Google Scholar 

  23. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene. 2003;22(56):8999–9006. doi:10.1038/sj.onc.1207111.

    Article  CAS  PubMed  Google Scholar 

  24. Abubaker J, Bavi P, Al-Haqawi W, et al. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol. 2009;219(4):435–445. doi:10.1002/path.2625.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Reza Mahdian MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zolfaghari, N., Shahbazi, S., Torfeh, M. et al. Identification of Differentially Expressed K-Ras Transcript Variants in Patients With Leiomyoma. Reprod. Sci. 24, 1438–1443 (2017). https://doi.org/10.1177/1933719116689596

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/1933719116689596

Keywords

Navigation